Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation.
Phase II study for treatment of patients with relapsed or primary refractory aggressive B-
cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for
autologous stem cell transplantation. Aim is to find response rates and duration of
combination chemotherapy (bendamustine/rituximab) in patients with relapsed or refractory CD
20 positive B cell NHL.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Martin Mohren, PD
University of Magdeburg, Department of Hematology and Oncology
Germany: Ethics Commission